New research has found that drinking two to three cups of coffee a day may protect an individual from cardiovascular illness and even an early death. Peter Kistler, head of clinical electrophysiology research at the Baker Heart and Diabetes Institute and author of the study, stated that findings suggest that the moderate consumption of instant, ground and decaffeinated coffee was part of a healthy lifestyle.
Kistler explained that while coffee contained caffeine, which was well-known, it also contained more than 100 other biologically active components.
Prior research has found that the mild intake of black coffee, which constitutes three to five cups of coffee a day, has been shown to reduce the risk of heart disease as well as Parkinson’s disease, Alzheimer’s, liver disease, type 2 diabetes and prostate cancer.
For their study, the researchers obtained data from the UK Biobank, which contained consumption preferences for coffee from about 450,000 individuals who had no history of arrhythmia or cardiovascular illness at the beginning of the study. The researchers divided the individuals into four groups: those who drank caffeinated instant coffee, those who consumed caffeinated ground coffee, those who preferred decaffeinated coffee and those who didn’t drink coffee at all.
They then looked at medical and death records for reports of stroke, cardiovascular disease, arrhythmia and death after an estimated 12 years. After the researchers adjusted for age, high blood pressure, ethnicity, diabetes, sex, obstructive sleep apnea, obesity, tea and alcohol consumption, and smoking status, they discovered that all coffee types were associated with a reduction in death from any cause.
In their statement, the researchers highlighted that drinking two to three cups of coffee daily was linked to a significant reduction in early death, in comparison to individuals who didn’t drink coffee at all.
The researchers also observed considerable reductions in the risk for congestive heart failure, coronary heart disease and stroke for all three coffee types. The consumption of ground coffee reduced the risk of death by 27% while decaffeinated reduced the risk by 14% and instant caffeinated coffee decreased this risk by 11%.
However, the report also highlighted that only instant and ground coffee with caffeine decreased the risk of experiencing an arrhythmia, which is an irregular heartbeat. The findings indicated that decaffeinated coffee did not reduce that risk.
The study’s main limitation was that the consumption of coffee was self-reported at one point in time. The researchers published their findings in the “European Journal of Preventive Cardiology.”
Technologies to ease the diagnosis and detection of heart conditions are improving at a fast pace. For example, HeartBeam Inc. (NASDAQ: BEAT) is awaiting FDA approval for its proprietary software, which is designed to improve the accuracy and speed at which heart attacks can be detected.
NOTE TO INVESTORS: The latest news and updates relating to HeartBeam Inc. (NASDAQ: BEAT) are available in the company’s newsroom at https://ibn.fm/BEAT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
